The Formula is outperforming all of the key benchmarks to start 2019.
The Formula is concerned with finding undervalued biotechs that (1) possess [an] asset[s] with therapeutic differentiation, (2) are likely to succeed in the clinic and/or on the market, and (3) are near sustained positive cashflow.
With all that said, I am still prone to error like anyone else, but quickly learning from mistakes.
I am accepting research requests from subscribers only. These requests will be published on Seeking Alpha (unbiased reviews/takes/etc. of the particular topic).
Do you have an itch to research something in particular before pulling the trigger on an interesting stock? Put me to the test and let me do some digging for you.
A Subscription To The Formula Includes:
- Exclusive, thorough, and reliable biotech research into risk averse conviction ideas (at least one new idea per month)
- Public article requests (I will research/write about topics/biotechs you wish me to & publish a Seeking Alpha article)
- Premium content that is not readily available to investors
- A model portfolio of my top biotechnology conviction picks with monthly updates
- A live chat with daily contributor messages/feedback and a growing community of informed, passionate investors
- Exclusive & frequent literature reviews (we review new articles/data and follow our drugs closely!)
- Instant access to all of my past articles on Seeking Alpha
Act now & try a free, no-risk 2-week trial today by clicking the flask below!